Jan 8, 2025 | Press Releases
Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a...
Jan 6, 2025 | Press Releases
CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in...
Dec 10, 2024 | Press Releases
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without needing electronics or software. NeurAxis Inc. will begin the process of commercially marketing RED and expects initial...
Nov 12, 2024 | Press Releases
Conference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing...
Nov 5, 2024 | Press Releases
CARMEL, Ind., Nov. 05, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in...
Nov 4, 2024 | Press Releases
Clearance expands indication for use from 11-18 year olds to 8-21 year olds; and from 3 devices, not to exceed 4 weeks, to 1 device per week for 4 weeksCARMEL, Ind., Nov. 04, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the...
